UnknownNot applicableNCT02392520

Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS)

Studying Ovarian hyperstimulation syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Eugonia
Principal Investigator: George T Lainas, MD
Barts and The London NHS Trust (ART Unit)
Intervention: cetrorelix (cetrotide)(drug)
Enrollment: 40 target
Eligibility: 18-49 years · FEMALE
Timeline: 2015 – 2016

Study locations (1)

Eugonia Unit of Assisted Reproduction, Athens, Greece

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02392520 on ClinicalTrials.gov

Other trials for Ovarian hyperstimulation syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT07043322
Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome
Tanta University

See all trials for Ovarian hyperstimulation syndrome →

← Back to all trials